Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma

References

• Fonseca R, Stewart KA. Targeted therapeutics for multiple myeloma. The arrival of a risk-stratified approach. Mol Cancer Ther 2007; 6:802 - 810
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74 - 108
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860 - 1873
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105:358 - 360
   PubMed Web of Science ®Google Scholar
• Chng WJ, Price-Troska T, Gonzalea-Paz N, Van Wier S, Jacobus S, Blood E, et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 13:582 - 584
   Web of Science ®Google Scholar
• Chang H, Yeung J, Qi C, Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous p53 deletion and poor survival for multiple myeloma. Br J Haematol 2007; 138:324 - 329
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307 - 310
   PubMed Web of Science ®Google Scholar
• Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002; 14:86 - 91
   PubMed Web of Science ®Google Scholar
• Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407:777 - 783
   PubMed Web of Science ®Google Scholar
• Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408:433 - 439
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14:5318 - 5324
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonist reveals aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103:18888 - 18893
   Web of Science ®Google Scholar
• Shangary S, Wang S. Small molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49:223 - 241
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844 - 848
   PubMed Web of Science ®Google Scholar
• Shangary S, Qin D, McEachem D, Liu M, Miller RS, Qiu S, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105:3933 - 3938
   PubMed Web of Science ®Google Scholar
• Saha MN, Micallef J, Qiu L, Chang H. Pharmacological activation of the p53 pathway in hematological malignancies. J Clin Pathol 2010; 63:204 - 209
   PubMed Web of Science ®Google Scholar
• kojima K, konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005; 106:3150 - 3159
   PubMed Web of Science ®Google Scholar
• Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A, et al. Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107:4122 - 4129
   PubMed Web of Science ®Google Scholar
• Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castaño E, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107:4109 - 4114
   PubMed Web of Science ®Google Scholar
• Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild type p53 and overexpression of MDM2. Leukemia 2008; 22:730 - 739
   PubMed Web of Science ®Google Scholar
• Drakos E, Thomaids A, Medeiros LJ, Li J, Leventaki V, Konopleva M, et al. Inhibition of p53-murine double minute-2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 2007; 13:3380 - 3387
   PubMed Web of Science ®Google Scholar
• Drakos E, Atsaves V, Schlette E, Li J, Papanastasi I, Rassidakis GZ, et al. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia 2009; 23:2290 - 2299
   PubMed Web of Science ®Google Scholar
• Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609 - 3617
   PubMed Web of Science ®Google Scholar
• Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009; 15:7153 - 7160
   PubMed Web of Science ®Google Scholar
• Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010; 9:937 - 945
   Google Scholar
• Schuler M, Green DR. Transcription, apoptosis and p53: catch-22. Trends Genet 2005; 21:181 - 187
   Web of Science ®Google Scholar
• Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006; 45:409 - 415
   PubMed Web of Science ®Google Scholar
• Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995; 80:293 - 299
   PubMed Web of Science ®Google Scholar
• Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11:577 - 590
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26:1324 - 1337
   PubMed Web of Science ®Google Scholar
• Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303:1010 - 1014
   PubMed Web of Science ®Google Scholar
• Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bax and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6:443 - 450
   PubMed Web of Science ®Google Scholar
• Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3A induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108:993 - 1000
   PubMed Web of Science ®Google Scholar
• Vaseva A, Natalia DM, Ute MM. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell cycle 2009; 8:1711 - 1719
   PubMed Web of Science ®Google Scholar
• Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription independent mechanism. Blood 2008; 112:3827 - 3834
   PubMed Web of Science ®Google Scholar
• Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55:96 - 107
   PubMed Web of Science ®Google Scholar
• Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003; 1:993 - 1000
   PubMed Web of Science ®Google Scholar
• Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced PUMA upregulation. Leukemia 2005; 19:427 - 434
   PubMed Web of Science ®Google Scholar
• Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279:53015 - 53022
   PubMed Web of Science ®Google Scholar
• Yaari-Stark S, Shaked M, Nevo-Caspi Y, Jacob-Hircsh J, Shamir R, Rechavi G, et al. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc. Int J Cancer 2010; 126:2268 - 2281
   PubMed Web of Science ®Google Scholar
• Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5:191 - 199
   PubMed Web of Science ®Google Scholar
• Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247 - 3257
   PubMed Web of Science ®Google Scholar
• Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21:2613 - 2622
   PubMed Web of Science ®Google Scholar
• Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y, et al. Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 2005; 280:19166 - 19176
   PubMed Web of Science ®Google Scholar
• Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria: a potential role in apoptotic signaling. J Biol Chem 2000; 275:16202 - 16212
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Diehl JA. Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 2006; 38:317 - 332
   PubMed Web of Science ®Google Scholar
• Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006; 34:7 - 11
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, et al. Stimulation of the stress-activated mitogenactivated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res 1996; 79:162 - 173
   PubMed Web of Science ®Google Scholar
• Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, et al. Stress and radiation induced activation of multiple intracellular signaling pathways. Radiation Res 2003; 159:283 - 300
   PubMed Web of Science ®Google Scholar
• Du P, Kibbe WA, Lin SM. Lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24:1547 - 1548
   PubMed Web of Science ®Google Scholar
• Bolstad BM, Irizarry RA, Astrand M, Speed TP. A Comparison of Normalization Methods for High Density Oligonucleotide Array Data Based on Bias and Variance. Bioinformatics 2003; 19:185 - 193
   PubMed Web of Science ®Google Scholar
• Smyth GK. Linear models and empirical Bayes methods for assessing differentially expressed in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:3
   PubMedGoogle Scholar